Literature DB >> 18657325

The ageing and myasthenic thymus: a morphometric study validating a standard procedure in the histological workup of thymic specimens.

Philipp Ströbel1, Regina Moritz, Maria Isabel Leite, Nick Willcox, Wen-Yu Chuang, Ralf Gold, Wilfred Nix, Berthold Schalke, Reinhard Kiefer, Hans-Konrad Müller-Hermelink, Alfred Jaretzki Iii, John Newsom-Davis, Alexander Marx.   

Abstract

The thymus is believed to play an important role in the pathogenesis of myasthenia gravis (MG). The 80% of MG patients with anti-acetylcholine receptor autoantibodies fall into three clinical subgroups: 1) thymoma; 2) early-onset MG (<age of 40; EOMG) and 3) late-onset (LOMG; onset after 40). Thymectomy is widely used in EOMG, but its benefits have not been established in randomized controlled trials. A multicenter international trial (MGTX) currently seeks to determine whether thymectomy reduces corticosteroid requirements, and to look for correlations with thymic histology. We here describe the validated, standardized histological workup and reporting system used in this trial.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18657325     DOI: 10.1016/j.jneuroim.2008.06.017

Source DB:  PubMed          Journal:  J Neuroimmunol        ISSN: 0165-5728            Impact factor:   3.478


  9 in total

1.  Two-year outcome of thymectomy in non-thymomatous late-onset myasthenia gravis.

Authors:  Akiyuki Uzawa; Naoki Kawaguchi; Tetsuya Kanai; Keiichi Himuro; Fumiko Oda; Shigetoshi Yoshida; Ichiro Yoshino; Satoshi Kuwabara
Journal:  J Neurol       Date:  2015-02-17       Impact factor: 4.849

Review 2.  [True thymic hyperplasia : Differential diagnosis of thymic mass lesions in neonates and children].

Authors:  C-A Weis; B Märkl; T Schuster; K Vollert; P Ströbel; A Marx
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

3.  Radioligand-binding assay reveals distinct autoantibody preferences for type I interferons in APS I and myasthenia gravis subgroups.

Authors:  Liv Hapnes; Nick Willcox; Bergithe E V Oftedal; Jone F Owe; Nils Erik Gilhus; Anthony Meager; Eystein S Husebye; Anette S Bøe Wolff
Journal:  J Clin Immunol       Date:  2011-11-30       Impact factor: 8.317

4.  Effect of thymectomy in elderly patients with non-thymomatous generalized myasthenia gravis.

Authors:  Seung Woo Kim; Young-Chul Choi; Seung Min Kim; Hyo Sup Shim; Ha Young Shin
Journal:  J Neurol       Date:  2019-02-06       Impact factor: 4.849

5.  Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy.

Authors:  Anna Kostera-Pruszczyk; Hubert Kwiecinski
Journal:  J Neurol       Date:  2009-06-23       Impact factor: 4.849

6.  Histopathology of thymectomy specimens from the MGTX-trial: Entropy analysis as strategy to quantify spatial heterogeneity of lymphoid follicle and fat distribution.

Authors:  Cleo-Aron Weis; Inmaculada B Aban; Garry Cutter; Henry J Kaminski; Christoph Scharff; Benedict W Grießmann; Maria Deligianni; Klaus Kayser; Gil I Wolfe; Philipp Ströbel; Alexander Marx
Journal:  PLoS One       Date:  2018-06-13       Impact factor: 3.240

Review 7.  Gut Microbiota as Regulators of Th17/Treg Balance in Patients With Myasthenia Gravis.

Authors:  Pan Chen; Xiangqi Tang
Journal:  Front Immunol       Date:  2021-12-23       Impact factor: 7.561

Review 8.  Clinical features, pathogenesis, and treatment of myasthenia gravis: a supplement to the Guidelines of the German Neurological Society.

Authors:  Nico Melzer; Tobias Ruck; Peter Fuhr; Ralf Gold; Reinhard Hohlfeld; Alexander Marx; Arthur Melms; Björn Tackenberg; Berthold Schalke; Christiane Schneider-Gold; Fritz Zimprich; Sven G Meuth; Heinz Wiendl
Journal:  J Neurol       Date:  2016-02-17       Impact factor: 4.849

9.  Ectopic germinal centers in the thymus accurately predict prognosis of myasthenia gravis after thymectomy.

Authors:  Johannes Dunkel; Anni Tuulasvaara; Joona Sarkkinen; Antti Huuskonen; Sari Atula; Eliisa Kekäläinen; Sini M Laakso
Journal:  Mod Pathol       Date:  2022-03-25       Impact factor: 8.209

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.